Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells

BACKGROUND: Due to the frequent dysregulation of the PI3K/AKT/mTOR signaling pathway, mTOR represents a suitable therapeutic target in hepatocellular carcinoma (HCC). However, emerging data from clinical trials of HCC patients indicate that mTOR inhibition by RAD001 (Everolimus) alone has only moder...

Full description

Saved in:
Bibliographic Details
Main Authors: Grabinski, Nicole, Ewald, Florian, Hofmann, Bianca T, Staufer, Katharina, Schumacher, Udo, Nashan, Björn, Jücker, Manfred
Format: Artigo
Language:Inglês
Published: BioMed Central 2012
Subjects:
Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3545733/
https://ncbi.nlm.nih.gov/pubmed/23167739
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1476-4598-11-85
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items